Nieuwdorp M, van Nood E, Speelman P, van Heukelem H A, Jansen J M, Visser C E, Kuijper E J, Bartelsman J F W M, Keller J J
Academisch Medisch Centrum/Universiteit van Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam.
Ned Tijdschr Geneeskd. 2008 Aug 30;152(35):1927-32.
To study the effect of treating recurrent Clostridium difficile-associated diarrhoea (CDAD) with a suspension of donor faeces.
Uncontrolled interventional study.
Patients that, despite adequate antibiotic therapy, had developed at least 2 recurrences ofCDAD, including at least one recurrence that had been treated with a vancomycin tapering regimen, were included in the study. Relatives or volunteers served as faeces donor. All donors were previously examined for the presence of HIV, hepatitis B- and C-virus, and acute infection with cytomegalovirus or Epstein-Barr virus. The donor faeces were examined for the presence of C. difficile, Yersinia, Campylobacter, Shigella, Salmonella, and parasites. Before the infusion of donor faeces, the patients were treated for 4 days with vancomycin 500 mg q.i.d., followed by colon lavage. The suspension of 150 g of donor faeces dissolved in 300-400 ml of NaCl was infused into the jejunum via a duodenal catheter or into the caecum via colonoscopy.
7 CDAD patients were included and treated, including 2 with the hypervirulent C. difficile-strain PCR ribotype 027, toxinotype III. In 5 patients, the defaecation frequency returned to normal almost immediately after treatment and the cultures and toxin tests for C. difficile were repeatedly negative. In the remaining 2 patients, the treatment was successful after a repeated infusion of faeces from a different donor.
Treatment with donor faeces seems promising for patients who develop repeated recurrences despite adequate therapy and could be valuable in the future during (local) epidemics of the PCR ribotype 027 strain. A randomised nationwide study (FECAL trial) has been started in order to determine the efficacy of this treatment.
研究用供体粪便悬液治疗复发性艰难梭菌相关性腹泻(CDAD)的效果。
非对照干预性研究。
尽管接受了充分的抗生素治疗,但仍至少复发2次CDAD(包括至少1次用万古霉素递减方案治疗的复发)的患者纳入本研究。亲属或志愿者作为粪便供体。所有供体之前均接受了HIV、乙型和丙型肝炎病毒检测,以及巨细胞病毒或EB病毒急性感染检测。对供体粪便进行艰难梭菌、耶尔森菌、弯曲杆菌、志贺菌、沙门菌和寄生虫检测。在输注供体粪便前,患者先用万古霉素500mg每日4次治疗4天,随后进行结肠灌洗。将150g供体粪便溶解于300 - 400ml氯化钠溶液中的悬液通过十二指肠导管注入空肠或通过结肠镜注入盲肠。
7例CDAD患者纳入并接受治疗,其中2例为高毒力艰难梭菌菌株PCR核糖型027、毒素型III。5例患者治疗后排便频率几乎立即恢复正常,艰难梭菌培养和毒素检测多次呈阴性。其余2例患者经再次输注不同供体的粪便后治疗成功。
对于尽管接受了充分治疗仍反复复发的患者,用供体粪便治疗似乎很有前景,并且在未来PCR核糖型027菌株的(局部)流行期间可能很有价值。一项全国性随机研究(粪便试验)已启动,以确定这种治疗方法的疗效。